Current therapeutic approaches face limitations in tissue tropism, toxicity, and payload size when targeting intracellular proteins, which constitute a significant portion of the body's proteins and key disease pathway targets. Existing technologies struggle to introduce functional proteins into specific cells or tissues, hindering effective treatment of various diseases.

Edity Therapeutics is developing a platform that leverages engineered immune cells to deliver therapeutic proteins directly into the cytoplasm of diseased cells, enabling intracellular reprogramming. The technology integrates therapeutic proteins into the perforin-granzyme pathway for targeted delivery to the cytosol of target cells. By redesigning immune cells to deliver protein therapeutics, Edity aims to address previously inaccessible intracellular targets and modulate disease pathways through protein replacement, target modulation, genetic correction, and protein gain of function. The platform is designed to work with T-cells and NK cells and can use CAR, TCR, or similar modalities for homing and activation.

Engineered immune cells for targeted delivery of therapeutic proteins into the cytoplasm of diseased cells.

Integration of therapeutic proteins into the perforin-granzyme pathway for direct delivery to the cytosol.

Compatible with allogeneic approaches.

Can be used with T-cells and NK cells.

Utilizes CAR, TCR, or similar modalities for homing and activation.

AI-designed pro-inflammatory proteins to reprogram the tumor microenvironment.

The primary target audience includes researchers and clinicians focused on developing novel therapies for cancer, genetic disorders, and regenerative medicine, as well as pharmaceutical companies seeking innovative drug delivery platforms.